Abstract Library

#4636 Maximising the use of pancreatic enzyme replacement therapy (PERT) among patients with gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) and exocrine pancreatic insufficiency (EPI)

Introduction: Patients with GEPNENs frequently develop EPI due to surgical resection or use of somatostatin analogues (SSAs), however it is significantly underdiagnosed. Untreated EPI has significant impact on overall quality of life with patients with GEPNENs.

Conference:

Presenting Author:

Authors: Grewal U, Chandar A,

Keywords: Pancreatic insufficiency, Pancreatic enzyme replacement therapy, Gastroenteropancreatic neuroendocrine neoplasm,

#4249 Factors associated with post-operative pancreatic insufficiency after distal pancreatectomy for localised non-functioning pancreatic neuroendocrine tumors (NF-PanNET)

Introduction: Pancreatic Neuroendocrine Tumors (pNETs) are rare neoplasms, often indolent in nature. Surgery is the backbone of curative treatment for localised panNETs. As the majority of these patients are cured by surgery, the development of long-term complications such as post-operative pancreatic insufficiency is critical.

Conference:

Presenting Author: Battistella A

Authors: Battistella A, Partelli S, Andreasi V, Muffatti F, Tamburrino D,

Keywords: PanNET, post-operative pancreatic insufficiency, distal pancreatectomy,

#4171 Prevalence of sarcopenia in patients with advanced intestinal neuroendocrine neoplasms at time of diagnosis

Introduction: Sarcopenia is defined as the loss of muscle mass, strength, and physical performance. First-line therapy for NENs includes somatostatin analogues (SSAs), which could be responsible for malabsorption conditions (e.g. exocrine pancreatic insufficiency - EPI), that can affect clinical outcomes and treatment response. However, the relationship between sarcopenia and NENs is still lacking in the literature.

Conference:

Presenting Author: Marasco M

Authors: Romano E, Polici M, Lerose F, Marasco M, Nardacci S,

Keywords: malnutrition, sarcopenia, somatostatin analogues, exocrine pancreatic insufficiency,

#1837 Evaluation of Faecal Elastase 1 in Symptomatic Patients with Neuroendocrine Tumours

Introduction: There is limited data on exocrine pancreatic insufficiency in patients on somatostatin analogues(SSA) which affects quality of life in NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Khan M

Authors: Chaudhry R, Newbould R, Williams M, Reid K, Donnelly L,

Keywords: Quality of life, Steatorrhoea, Diarrhea, SST,

#1769 Minimal Risk of Persistent or Recurrent Hypoglycemia after MEN1-Related Insulinoma Surgery. A Large International Cohort Study

Introduction: Current literature states that 15-30% of the MEN1 patients suffer from hypoglycemia after insulinoma surgery.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Nell S

Authors: Nell S, Goudet P on behalf of the French Endocrine Tumor Study Group (GT -, Vella A, Bartsch D, Perrier N,

Keywords: MEN1,